Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Anacor Pharmaceuticals, Inc. (ANAC) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/11/2016 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
07/11/2016 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend]
07/05/2016 15-12B Form 15-12B - Securities registration termination [Section 12(b)]
06/24/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
06/24/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
06/24/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
06/24/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
06/24/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
06/24/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
06/24/2016 POS AM Form POS AM - Post-Effective amendments for registration statement
06/24/2016 POS AM Form POS AM - Post-Effective amendments for registration statement
06/24/2016 POS AM Form POS AM - Post-Effective amendments for registration statement
06/24/2016 POS AM Form POS AM - Post-Effective amendments for registration statement
06/24/2016 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party [Amend]
06/24/2016 8-K Quarterly results
06/24/2016 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
06/08/2016 8-K Form 8-K - Current report
06/07/2016 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party [Amend]
05/26/2016 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements
05/26/2016 SC TO-T Form SC TO-T - Tender offer statement by Third Party
05/19/2016 SC14D9C Form SC14D9C - Written communication relating to third party tender offer
05/16/2016 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party
05/16/2016 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger among Anacor Pharmaceuticals, Inc., Pfizer Inc. and Quattro Merger Sub Inc",
"Pfizer to Acquire Anacor"
05/10/2016 10-Q Quarterly Report for the period ended March 31, 2016
05/10/2016 8-K Form 8-K - Current report
04/29/2016 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/06/2016 8-K Form 8-K - Current report
03/31/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "ANACOR PHARMACEUTICALS, INC. ANNOUNCES PRICING OF OFFERING OF $250 MILLION OF 2.00% CONVERTIBLE SENIOR NOTES DUE 2023"
03/30/2016 8-K Form 8-K - Current report
03/22/2016 8-K Form 8-K - Current report
02/29/2016 10-K Annual Report for the period ended December 31, 2015
02/29/2016 8-K Quarterly results
Docs: "ANACOR PHARMACEUTICALS REPORTS 2015 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS · Submitted NDA to the FDA on January 7, 2016 seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults · Recognized $69.7 million in total KERYDIN® distribution and commercialization agreement revenues for the year ended December 31, 2015"
02/24/2016 8-K Other Events
02/11/2016 SC 13G/A Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy